This company develops medical instruments for rapid infectious disease identification. Their technology provides diagnostic results for microbial identification in under 15 minutes. This significantly reduces the turnaround time compared to conventional microbiological techniques.
Funding
$220K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for identifying antimicrobial resistance (AMR) rely on time-consuming techniques like bacterial cultures and biochemical assays, often delaying results by 24-72 hours. This delay can lead to patients being treated with ineffective antibiotics, increasing morbidity, mortality, and the risk of spreading resistant microorganisms.
Solution
CCI Photonics offers a portable diagnostic medical device that rapidly identifies pathogens responsible for AMR in in-vitro and biofluid samples. Their β-Prototype uses a novel approach to AMR diagnostics, providing results with over 90% accuracy within 15 minutes. This rapid identification enables healthcare providers to quickly detect drug-resistant infections and administer appropriate treatments, improving patient outcomes and reducing the spread of AMR. The device leverages a unique biological-spectral database and AI-driven models for accurate and timely detection.
Target Audience
The primary target audience includes healthcare providers, hospitals, and clinical laboratories seeking rapid and accurate detection of antimicrobial resistance.
Features
- Portable diagnostic medical device for rapid AMR identification
- Detects pathogens in in-vitro and biofluid samples
- Provides results in as little as 15 minutes
- Achieves over 90% accuracy in AMR detection
- Employs a unique biological-spectral database
- Utilizes AI-driven models for pathogen identification